FDA Consumer Health Product Enforcement Roundup
This article was originally published in The Tan Sheet
Executive Summary
New Zealand firm’s misbranded sunscreens, GMP problems; concussion treatment claims for Re:Mind; DMBA spotted in TruVision supplements; ED ingredient in Rhino supplements, other recalls; and formula selenium level effective date.
You may also be interested in...
Water Making Cancer Claim On Import Alert: Health And Wellness Industry News
TruVision warned on GMPs; UK regulators tell TV personality to disclose her social media endorsement of vitamin firm Convits; ThermoLife’s six-year litigation against Gaspari ends; and more news in brief.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.